Probatebeta
Target

PDGFRB

Platelet-derived growth factor receptor beta

As of the edition of 20 October 2026, PDGFRB (platelet-derived growth factor receptor beta, UniProt P09619) has 36 drugs tested at it and 39 companies on the list, 19 on route A and 6 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P09619
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
8
Disease areas
Cancer; Digestive system; Urinary and reproductive; Pregnancy and women's health; Blood and lymph; Lungs and airways; Skin and connective tissue; Hormones
Registered trials of its drugs
2,568

Drugs at this target

StatusCount
Marketed10
Active4
Went quiet7
Stopped14
Status not established1
Total36
DrugStatusFurthest phaseUS protection
SorafenibMarketedPhase 4Ends 2027
SunitinibMarketedPhase 4none listed
Dasatinib anhydrousMarketedPhase 4Ended 2026
RegorafenibMarketedPhase 4Ends 2032
PazopanibMarketedPhase 4none listed
NintedanibMarketedPhase 4Ends 2027
CediranibStoppedPhase 3none listed
FamitinibStoppedPhase 3none listed
DovitinibActivePhase 3none listed
MidostaurinMarketedPhase 3none listed
QuizartinibMarketedPhase 3Ends 2030
TivozanibMarketedPhase 3Ends 2028

12 of 36 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A19
Route B6
Engaged9
Undetermined5
Total on the list39
Three companies on route A or B, with the route only
CompanyRoute
PfizerRoute B
Bristol Myers SquibbRoute B
AstraZenecaRoute A

The other 36 companies at PDGFRB

In the product

39 companies in all; 36 are not named here, and no score is.

See the 39 companies at PDGFRB, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at PDGFRB

Other targets in cancer

Companies holding approvals at PDGFRB